Pay in 4 interest-free payments of $5.75 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
The use of this medicine effectively manages type 2 diabetes and encourages weight loss through its ability to regulate sugar content in the blood and suppress appetite
Developer: Eli Lilly and Company Classification: Triple Agonist (GIP/GLP-1/Glucagon receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials Expected FDA Approval: Q3 2026 to Q1 2027 Developer: Boehringer Ingelheim Classification: Dual Agonist (Glucagon/GLP-1 receptors) Administration: Once-weekly subcutaneous injection Development Status: Phase 3 clinical trials (SYNCHRONIZE program) Regulatory Status: FDA Breakthrough Therapy designation for MASH Retatrutide emerged from Eli Lillys research into multi-receptor agonism
It melts into your skin to brighten dullness, even out tone, and give you that glass-skin glow Lightweight yet deeply nourishing Brightens & improves skin tone Boosts natural radiance Leaves skin soft, smooth & luminous Say hello to healthy, glowing skin every day
plantarum KY1032 a multi-strain blend of L
Our advanced formula features 800 mg L-Carnitine plus 400 mg Alpha Lipoic Acid per serving in Non-GMO and Gl
US$ 29.96
US$ 24.87
US$ 26.74
US$ 23.61
US$ 21.32
US$ 29.45
US$ 28.51
